key: cord-0999313-lkntzy3v
authors: A, Di Caro; F, Cunha; N, Petrosillo; NJ, Beeching; O, Ergonul; E, Petersen; MPG, Koopmans
title: SARS-CoV-2 escape mutants and protective immunity from natural infections or immunizations
date: 2021-03-29
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.03.011
sha: e55f1feab7cfbc0f0e74c3e29dd6c66b7ae45222
doc_id: 999313
cord_uid: lkntzy3v

Although coronaviruses have lower mutation rates than other respiratory RNA viruses, the scale of the pandemic has brought the importance of viral evolution for coronaviruses to centre stage. Three recently detected SARS-CoV-2 lineages (B.1.1.7, B.1.351, and P.1), have been scrutinized because they are unusually divergent and each possesses a unique constellation of mutations of potential biological importance, several of which are in the gene coding for the Spike protein. We briefly summarize the current knowledge on these variants, and their possible implications.

, and GISAID [3] , respectively, all widely used in the field. Updates of detections of spike gene mutations for each GISAID clade are posted daily on the "CoVariants" website [3, 9] , together with geographic maps of their proportional distribution [10] , and visualised through collaboration with Nextstrain. The current version of the Nextstrain data visualisation software allows switching between GISAID and PANGO lineage designations, and the WHO is working on a unifying system for nomenclature. [table 1, [11] [12] [13] [14] [15] . In addition, some viral genomes of the B.1.1.7 lineage have been observed that acquired the E484K mutation which is thought to be linked to immune evasion [15] [16] [17] .

Mutations that cause conformational changes in the spike protein receptor binding domain (RBD), and which affect binding to key host tissue receptors, are expected to impact on infectivity. For the above variants, there is some evidence that the binding affinity is increased, and that there may be a selective advantage increasing transmissibility. A recent study plotted the binding affinity to ACE2 of all RBD mutations against their incidence in the population and showed a strong correlation between the two [18] . It also showed how further evolution might increase binding affinity even further [19] . Such mutations are also considered to have the most important impact on the effects of neutralizing antibodies. One study found that binding by polyclonal serum antibodies is affected by mutations in three main epitopes in the RBD [1] . The most important site is E484, where neutralization by some convalescent and vaccinee sera is reduced >10-fold by several mutations, including one in emerging viral lineages in South Africa (B. 1.351, also named 501.V2) and Brazil (B.1.1.28.1, also named P1) [1, 20] . A study using VSV pseudovirus expressing different variants of the SARS-CoV-2 spike protein found that VSV pseudoviruses with spike containing K417N-E484K-N501Y-D614G and full B.1.351 mutations were less easily neutralized with 2.7 and 6.4-fold lower neutralizing antibody titres respectively, when compared to the nonvariant VSV pseudovirus used in this study [21] .

While some of these observations are reason for concern, the field is very young, and careful evaluation of the effects is needed, for instance on the impact of emergence of variants on vaccine J o u r n a l P r e -p r o o f efficacy. In addition to neutralising and binding antibodies, SARS-CoV-2 infection also elicits a vast repertoire of T cell responses and dominant epitopes had the capacity to bind multiple HLA allelic variants [22] . A further study by the same authors found that "CD4+ and CD8+ T cell responses in convalescent COVID-19 subjects or COVID-19 mRNA vaccinees are not substantially affected by mutations found in the SARS-CoV-2 variants" [23] . A major limitation of that study is that all donors were recruited in California and had no known exposure to the escape variants first found in the UK, South Africa or Brazil. Therefore, we do not know if T cell responses elicited by previous SARS-CoV-2 infection or immunisation with the present "1 st generation" vaccines will be protective against infections with escape mutants.

The South African variant B.1.351

The B.1.351 lineage is present in 90% of recent infections for which sequence data was generated in South Africa, and has been associated with increased transmissibility [24] . Press reports indicate that it also may predominate in Botswana, Zimbabwe, Zambia, Namibia and Malawi [25] . An November 2020 [14] . A study from Brazil found that 76% of the population had been infected with SARS-CoV-2 by October 2020 [31] . The sharp increase in the number of COVID-19 hospital admissions seen in Manaus in January 2021 (3, 431 in Jan 1-19, 2021, vs 552 in Dec 1-19, 2020) indicates that immunity obtained during infection in mid to -late 2020 was not fully protective [32] . Little is known about the transmissibility of the P.1 lineage, but it shares several independently acquired mutations with the B.1.1.7 (N501Y) and the B.1.325 (K417N/T, E484K, N501Y) lineages first detected in the UK and South Africa, which seem to have increased transmissibility [13] . By now, the variant has been detected in 25 countries.

Moderna is exploring how their vaccine could be updated to incorporate sequences coding for the new variants of the spike protein [33] . Novavax is working on a booster and/or combination bivalent vaccine in response to the B.1.351 variant in South Africa [34] . BioNTech is looking to authorize "a new version of the Pfizer-BioNTech vaccine that would be better able to head off the variant in South Africa" [25] . Studies estimating the ability of vaccines to reduce transmission of different viral lineages continue to be essential [35] . A challenge will be when to decide to change the vaccine composition, as the dispersal is not uniform globally. Also, regulators are studying the regulatory process needed for vaccine updates.

The global expansion of SARS-CoV-2 and the continued circulation in partially immune populations has led to emergence of variants with some adaptive changes leading to increased transmissibility and / or decreased sensitivity to neutralising antibodies. The expanding number of people with immunity to SARS-CoV-2, following natural infection or immunisation, and the inequality of access to and / or application of interventions and vaccines is likely to create further immune pressure on the virus. Thus, the strategy by vaccine manufacturers to foresee the need for "second generation" vaccines covering the new mutants is reassuring. From a public health perspective, it is likely that we will need repeated immunisation rounds, like those already in place for influenza, with annual vaccines tailored to new variants. The challenge with SARS-CoV-2 is the global scale of J o u r n a l P r e -p r o o f

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

Insights from SARS-CoV-2 sequences

GSAID. hCoV-19 Spike Glycoprotein Mutation Surveillance Dashboard

European COVID-19 Data Platform

NCBI SARS-CoV-2 resource

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in a ferret model

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological

Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein. Virological.org

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Investigation of novel SARS-CoV-2 variant Variant of Concern 202012/01. Technical briefing 5. This briefing provides an update on the briefing of 14

SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity. bioRxiv

SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees

COVID-19: Inside the South African laboratory tracking the shape-shifting coronavirus

South Africa COVID vaccine results cause Novavax to begin work immediately on "a booster and/or combination bivalent vaccine". Science Speaks: Global ID News. A project of IDSA (Infectious Disease Society of America) Global Health

South African variant of COVID found in eight areas of England

Novavax Soars After Upbeat Results From Covid Vaccine Trial (2)

British Broadcasting Corporation, BBC. Covid-19: Novavax vaccine shows 89% efficacy in UK trials

J&J one-dose Covid vaccine is 66% effective

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. medRxiv 27 th

Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Moderna's vaccine is less potent against one coronavirus variant but still protective, company says

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19

Interpreting vaccine efficacy trial results for infection and transmission